HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Submit an electronic Letter to the Editor about this paper Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in ISI Web of Science Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via ISI Web of Science (11) Citing Articles via Google Scholar Google Scholar Articles by Ali, A. C. Y. Articles by Campbell, J. A. Search for Related Content PubMed PubMed Citation Articles by Ali, A. C. Y. Articles by Campbell, J. A. Related Collections General Clinical Chemistry Oak Ridge Conference Drug Monitoring and Toxicology

Interference of o-Raffinose Cross-Linked Hemoglobin with Routine Hitachi 717 Assays

Hemosol Inc., 115 Skyway Ave., Etobicoke, ON M9W 4Z4, Canada
^a author for correspondence: fax 416-798-0152

Hemoglobin interference in laboratory analyses due to hemolysis has been well characterized (1)(2)(3). Laboratory scientists are becoming sensitized to an additional iatrogenic cause of interference from hemoglobin. Stabilized hemoglobin-based oxygen carriers (HBOCs) have potential applications in trauma and emergency surgery, perioperative hemodilution, cardiopulmonary bypass, and hematopoiesis (4). Several of these products are in late clinical trials and are nearing marketing approvals. As a result, there has been increasing interest in the effects of these HBOCs on routine laboratory assays by clinical chemists and diagnostic reagent manufacturers.

This paper presents the results of a study that examined the effects of an HBOC, o-raffinose cross-linked hemoglobin (Hemolink^TM) on selected routine assays on the Hitachi 717 with reagents from Boehringer Mannheim Corp. (BMC). Hemolink is prepared from hemoglobin purified from outdated human red blood cells previously tested and released for use in transfusion. The purified hemoglobin reacts with o-raffinose, a polyaldehyde obtained through oxidation of raffinose (5)(6). As a result, two hemoglobin ß dimers are covalently cross-linked between amino groups within the 2,3-diphosphoglycerate binding pocket to form stable hemoglobin tetramers (64 kDa). In addition, o-raffinose reacts with surface amino groups to form intermolecular linkages producing stable hemoglobin polymers (128–600 kDa). The final Hemolink preparation contains ~40% of the hemoglobin tetramer and ~60% of the hemoglobin polymers.

To study the effects of Hemolink on the measurement of routine analytes, . . . [Full Text of this Article]

Acknowledgments

References

The following articles in journals at HighWire Press have cited this article:

				A. A. Ali, G. S. Ali, J. M. Steinke, and A. P. Shepherd Co-Oximetry Interference by Hemoglobin-Based Blood Substitutes Anesth. Analg., April 1, 2001; 92(4): 863 - 869. [Abstract] [Full Text] [PDF]

				A. C. Y. Ali, C. C. Mihas, and J. A. Campbell Interferences of o-raffinose cross-linked hemoglobin in three methods for serum creatinine Clin. Chem., September 1, 1997; 43(9): 1738 - 1743. [Abstract] [Full Text] [PDF]

				C. M. Balion, P. A. Champagne, and A. C. Y. Ali Evaluation of HemogloBindTM for Removal of o-Raffinose Cross-Linked Hemoglobin (HemolinkTM) from Serum Clin. Chem., September 1, 1997; 43(9): 1796 - 1798. [Full Text]